Top Logistics Companies To Watch For 2016

Top Logistics Companies To Watch For 2016: Market Vectors Global Alternative Energy ETF (GEX)

Market Vectors-Global Alternative Energy ETF (the Fund) seeks to replicate as closely as possible the price and yield performance of the Ardour Global Index (Extra Liquid) (the Index). The Index, published by Ardour Global Indexes, LLC and calculated by Dow Jones Indexes, is a benchmark for the global alternative energy industry. The Index is a rules-based index that seeks to track the overall performance of a global universe of listed companies engaged in the alternative energy industry. As of April 2007, the Index consisted of publicly traded stocks of 30 of the largest, most actively traded alternative energy companies from worldwide. Companies included in the Index generate over 50% of their revenues from alternative energy and/or related technologies, and are engaged in five core industry sectors: alternative energy resources (solar, wind, bio-fuels, water and geothermal), which constitute approximately 70% of the Index; distributed generation, which constitutes appro ximately 3% of the Index; environmental technologies related to alternative energy, which constitutes approximately 9% of the Index; energy efficiency, which constitutes approximately 4% of the Index, and enabling technologies, which constitutes approximately 14% of the Index.

The Index consists of the 30 stocks in the Ardour Global Index (Composite) with the highest average of daily trading volume and market capitalization. The Ardour Global Index (Composite) is a modified capitalization-weighted, float-adjusted index comprising publicly traded companies engaged in the production of alternative fuels and/or technologies related to the production of alternative energy power. The Fund will normally invest at least 80% of its total assets in stocks of companies primarily engaged in the business of alternative energy. The Fund, uti! lizing a passive or indexing investment approach, attempts to approximate the investment performance of the Index by investing in a port folio of securities that generally replicate the Index. The ! Fund will hold all of the securities, which comprise the Index in proportion to their weightings in the Index. The Fund will normally invest at least 95% of its total assets in securities that comprise the Index. Van Eck Associates Corporation serves as the investment advisor of the Fund.

Advisors' Opinion:

• [By Todd Shriber, ETF Professor]

  The news was predictably good for a pair of ETFs that should be known as "Tesla ETFs." The Market Vectors Global Alternatve Energy ETF (NYSE: GEX) and the First Trust NASDAQ Clean Edge Green Energy Index Fund (NASDAQ: QCLN) both traded higher on a down day for U.S. stocks, rising to within pennies of their previous 52-week highs.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-logistics-companies-to-watch-for-2016.html

Top Paper Stocks To Own Right Now

Top Paper Stocks To Own Right Now: Meadwestvaco Corporation (MWV)

MeadWestvaco Corporation (MWV) provides packaging solutions to the healthcare, personal care and beauty, food, beverage, home and garden, tobacco, and commercial print industries worldwide. The company?s Packaging Resources segment produces bleached paperboard, Coated Natural Kraft paperboard, and linerboard. Its Consumer Solutions segment designs and produces multi-pack cartons and packaging systems primarily for the beverage take-home and tobacco market. In addition, it offers a range of converting and consumer packaging solutions, including printed plastic packaging and injection-molded products used for personal care, beauty, and pharmaceutical products; and dispensing and sprayer systems for personal care, beauty, healthcare, fragrance, and home and garden markets. In addition, this segment has a pharmaceutical packaging contract with a mass-merchant, and manufactures equipment that is leased or sold to its beverage and dairy customers to package their products. The c ompany?s Consumer & Office Products segment manufactures, sources, markets, and distributes school and office products, time-management products, and envelopes in North America and Brazil through both retail and commercial channels. Its Specialty Chemicals segment manufactures, markets, and distributes specialty chemicals derived from sawdust and other byproducts of the papermaking process in North America, South America, and Asia. Its products include activated carbon used in emission control systems for automobiles and trucks, as well as for water and food purification applications, and performance chemicals used in printing inks, asphalt paving, adhesives, and lubricants for the agricultural, paper, and petroleum industries. MWV?s Community Development and Land Management segment involves in real estate development, forestry operations, and leasing activities. MeadWestvaco ! Corporation was founded in 1888 and is based in Glen Allen, Virginia.

Advisors' Opinion:

• [By ovenerio]

  The company has a current ROE of 14.5% which is higher than the industry median. Also, it is higher than the ones exhibit by Sealed Air Corp (SEE) and Sonoco Products Co (SON). In general, analysts consider ROE ratios in the 15-20% range as representing attractive levels for investment. So for investors looking at those levels, MeadWestvaco Corp (MWV) and Packaging Corp of America (PKG) could be the options. It is very important to understand this metric before investing, and it is important to look at the trend in ROE over time.

• [By Will Ashworth]

  I don't know about you but I definitely use several of its products on a regular basis. In fact, right here on my desk beside my computer is a small, Five Star notebook for jotting down ideas. I grew up on Hilroy notebooks, a brand brought to the table in its 2012 merger with MeadWestvaco's (MWV) Consumer and Office Products division. MWV shareholders received one-third of an ACCO share for every MWV share. Since the deal was completed, ACCO stock has lost 42% of its value.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-paper-stocks-to-own-right-now-3.html

Hot Dividend Stocks To Watch Right Now

Hot Dividend Stocks To Watch Right Now: Merck & Company Inc.(MRK)

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women's health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New ! Jersey.

Advisors' Opinion:

• [By John Udovich]

  However, biotech blogger Adam Feuerstein then wrote an article for The Street saying the data released "falls short of spectacular." He added that Gilead Sciences, Inc's (NASDAQ: GILD) Sovaldi, the only approved hepatitis C "nuc" on the market and Merck & Co. Inc's (NYSE: MRK) MK-3682 that was acquired when they bought Idenix Pharmaceuticals, both achieved larger viral load reductions faster than Achillion Pharmaceuticals' ACH-3422.

• [By Johanna Bennett]

  Talk about a blast from the past. After waiting for years, U.S. drug giant Merck & Co. (MRK) set loose clinical trial results at today's session of the American Heart Association's annual meeting showing that the cholesterol-lowering medication Vytorin, which combines the drug Zocor and Zetia into one pill, helped prevent heart attacks, strokes and other cardiovascular events.

  Bloomberg News

  The study results showed a modest benefit – a 6.4% reduction in cardiovascular events –in high-risk patients compared to those being treated with Zocor alone. But the data is regarded as a big deal for Zetia.

  Unlike Zocor, which is a member of the blockbuster statin class of cholesterol drugs, Zetia fights cholesterol by preventing its absorption from food. The data released today marks the first time a drug outside the statin family was shown to help lower the risk of serious cardiovascular problems.

  Sales of Vytorin and Zetia have suffered over the year amid patent expirations and questions about whether the drugs lowered LDL without improving cardiovascular outcomes.

  Share of Merck have gained rose 1% to $59.57 at 1:39 p.m.

  As Mark Schoenebaum, the pharmaceutical analyst at Evercore ISI, wrote in a note out today:

  The trial hit…The results today are positive for Merck’s Zetia and Vytorin but go beyond by suggesting that LDL lowering with drugs other than statins provides a cardi! ovascular! benefit (a reaffirming of the LDL hypothesis that was beginning to be questioned) and that LDL levels should possibly be driven lower than guidelines have recommended (below 70 mg/dl).  Today’s results add the first real data point to our understanding of the relationship between LDL reduction and outcomes at very low LDL levels…

  Schoenebaum also writes that today's study results bode well for other typed of cholesterol-lowering drugs now in R&D pipelines, namely the PCKSK9 inhibitors being developed b

• [By Ben Levisohn]

  In the Hepatitis-C wars, small setbacks for Johnson & Johnson (JNJ) and Merck (MRK) could be good news for Gilead Sciences (GILD).

  Getty Images

  What happened? For Johnson & Johnson, it was a decision by Japan’s ministry of health to ordered subsidiary Janssen Pharmaceuticals to put new warnings on the labels of Sovriad. RBC’s Michael Yee and team explain what that means for Gilead Sciences:

• [By Shauna O'Brien]

  Before Monday’s opening bell, Merck & Co., Inc. (MRK) released its third quarter financial results and full year outlook. While EPS beat analysts’ estimates, Q3 revenue fell short of expectations.

  MRK’s Earnings in Brief

  Merck reported third quarter earnings of $895 million, or 31 cents per share, down from $1.1 billion, or 38 cents per share, a year ago. Non-GAAP earnings dropped from 92 cents to 90 cents per share, but beat analysts’ estimate of 88 cents per share. Revenue for the quarter was $10.56 billion, down from $11.03 billion last year. On average, analysts expected to see revenue of $10.67 billion. Looking forward, MRK expects to see FY2014 GAAP earnings between $4.06 and $4.29 per share and non-GAAP earnings between $3.46 and $3.50 per share. Analysts expect to see Fy2014 earnings of  $3.47 per share. The company expects to see FY2014 revenue between $42.4 billion and $42.8 billion. Analysts expect to see $42.55 billion in revenue.!

  CEO ! Commentary

  Kenneth C. Frazier, chairman and CEO of Merck, commented: “Last October, we launched a multi-year initiative to transform Merck and build a platform for sustained, future growth. One year later, we delivered solid third-quarter results and are making steady progress in our transformation, including divesting non-core assets, reducing our expense base and investing in our promising new product launches and pipeline.”

  MRK’s Dividend

  Merck paid its last 44 cent dividend on October 7. We expect the company to declare its next dividend in November.

  Stock Performance

  Merck shares were up 39 cents, or 0.68%, during pre-market trading Monday. The stock is up 15.1% YTD.

  MRK Dividend Snapshot

  As of Market Close on October 24, 2014

  Click here to see the complete history of MRK dividends.

source from Top Stocks For 2015:http://www.topstocksblog.com/hot-dividend-stocks-to-watch-right-now-5.html

Top 10 High Dividend Stocks To Own For 2016

Top 10 High Dividend Stocks To Own For 2016: International Stem Cell Corp (ISCO)

International Stem Cell Corporation, incorporated on June 7, 2005 is a developmental-stage biotechnology company. The Company focused on therapeutic and biomedical product development. The Company's wholly owned subsidiary Lifeline Cell Technology, LLC (LCT) develops, manufactures and commercializes over 130 human cell culture products, including frozen human primary cells and the reagents (media) needed to grow, maintain and differentiate the cells, in order to address this market opportunity. The Company's scientists have used a technology called basal medium optimization to systematically produce optimized products designed to culture specific human cell types and to elicit specific cellular behaviors. The Company's wholly owned subsidiary Lifeline Skin Care, Inc. (LSC) develops, manufactures and markets cosmetic skin care products using an extract derived from its pluripotent stem cells.

Therapeutic Product Candidates

Using the Company 's technologies and know-how, the Company is exploring and creating a range of cell types that is useful in therapeutic treatments, which include Liver cells (hepatocytes) that may be used to treat a range of congenital and acquired liver diseases. Neuronal cells for potential treatment of Parkinson's disease and other central nervous system disorders, such as traumatic brain injury, stroke and Alzheimer's disease. Three-dimensional eye structures to treat degenerative retinal diseases, corneal blindness, and to accelerate corneal healing.

Skin Care Products

The Company's research scientists developed two skin care products, Defensive Day Serum and Recovery Night Serum, using an extract derived from human parthenogenic stem cells. Defensive Serum contains sunscreen, along with stem cell-derived ingredients. The day serum ! not only protects the skin from the aging effects of harsh light, but it continues to nurture the skin's collagen and fibro blasts to give noticeably firmer, smoother, younger-looking ! skin. The Recovery Night Serum is a nighttime therapy that complements the Defensive Day Serum. The night serum nurtures the skin's collagen and elastin and contains ingredients to defend against damaging free radicals, to help build firmer, smoother, younger and healthier-looking skin.

Research Products

The Company's Lifeline subsidiary produces and sells over 250 human cell culture products. These products include frozen human cells and stem cells and the reagents needed to grow, maintain and differentiate the cells. These human cell-based products are used domestically and internationally by research scientists in pharmaceutical, academic and government research organizations to study human disease and basic cell biology.

The Company competes with Genzyme Corporation, StemCell, Advanced Cell Technology Inc., Aastrom Biosciences, ViaCyte, Obagi, SkinCeuticals, SkinMedica, Murad, Lonza, Chemicon, Life Technologies, StemCell Techno logies, Merck, BioTime and Specialty Media.

Advisors' Opinion:

• [By Peter Graham]

  Small cap stocks Greenfield Farms Food Inc (OTCMKTS: GRAS), International Stem Cell Corp (OTCMKTS: ISCO) and Redpoint Bio Corporation (OTCMKTS: RPBC) have all been getting some extra attention lately in various investment newsletters. However, none of these small cap stocks appear to have been the subject or paid promotions or investor relations activities. So does that make any of them good bets for traders and investors alike? Here is a quick look and a reality check:

• [By John Udovich]

  Summer and the slow news for the market that usually comes with it is over with and both stem cell researchers or small  cap stem cell stocks like Advanced Cell Technology, Inc (OTCBB: ACTC), Neuralstem, Inc (NYSEMKT! : CUR), N! eoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO) and BioRestorative Therapies (OTCBB: BRTX) having news for investors and traders alike. Consider the following:

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-high-dividend-stocks-to-own-for-2016-2.html